INmune Bio: XPro1595 umabot sa white-matter MRI endpoint sa Ph2 MINDFuL Alzheimer’s trial

Phase 2 MINDFuL trial umabot sa exploratory chi-separation MRI white-matter biomarker endpoint na may statistically significant treatment effect sa full mITT population (p=0.0028, d=0.46, n=200) at mas malakas na epekto sa inflammation-enriched subgroup (p=0.0098, d=0.59, n=100). Ang resulta ay nagpapatunay ng target engagement sa myelin at sumusuporta sa precision-medicine strategy para sa paparating na Phase 2b/3 registrational program.

Mahahalagang fact

Na-file: Hun 2, 2026, 08:00 PM
Kaganapan: Topline na resulta
Direksyon: Positibo
Kumpanya: INMBINmune Bio Inc.
Asset: XPro1595
Pinagmulan: SEC 8-K
Kumpiyansa: May source
N ng buong mITT: 200
P-value ng buong mITT: 0.0028
N ng grupong pinayaman ng biomarker: 100
Laki ng epekto ng buong mITT: d=0.46
P-value ng grupong pinayaman ng biomarker: 0.0098
Laki ng epekto ng grupong pinayaman ng biomarker: d=0.59

Sipi mula sa source

EX-99.1 2 ea029332501ex99-1.htm PRESS RELEASE DATED JUNE 2, 2026 Exhibit 99.1 INmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer’s Trial XPro1595 showed a highly significant treatment effect in the full mITT population (p=0.0028; d=0.46; n=200), demonstrating broad tissue-level target engagement and treatment-related biological effect. Efficacy was further strengthened in biomarker-enriched patients with elevated levels of inflammation (p=0.0098; d=0.59; n=100) validating INmune’s precision-medicine approach and directly aligning with the design of the Phase 2b/3 registrational program. BOCA RATON, FL , June 02, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB), a late-stage biotechnology company fo

SEC 8-K

Higit pa tungkol sa asset na ito

May 14, 2026

12:00 PM

INMBINmune Bio Inc.

INmune Bio: FDA Fast Track para sa XPro sa maagang Alzheimer's

Designation ng FDAPress release ng kumpanya